162 related articles for article (PubMed ID: 38323765)
1. [Hypercalcemia: a practical review].
Barbry A; Masserey-Bonvin V; Petignat PA
Rev Med Suisse; 2024 Feb; 20(860):300-304. PubMed ID: 38323765
[TBL] [Abstract][Full Text] [Related]
2. A practical approach to hypercalcemia.
Carroll MF; Schade DS
Am Fam Physician; 2003 May; 67(9):1959-66. PubMed ID: 12751658
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of antiresorptive agents bisphosphonates and denosumab in mitigating hypercalcemia and bone loss in primary hyperparathyroidism: A systematic review and meta-analysis.
Rajput S; Dutta A; Rajender S; Mithal A; Chattopadhyay N
Front Endocrinol (Lausanne); 2023; 14():1098841. PubMed ID: 36817591
[TBL] [Abstract][Full Text] [Related]
4. Control of Refractory Hypercalcemia with Denosumab in a Case of Metastatic Parathyroid Carcinoma.
Çalapkulu M; Gul OO; Cander S; Ersoy C; Erturk E; Sagiroglu MF; Saraydaroglu O
J Coll Physicians Surg Pak; 2020 Jul; 30(7):757-759. PubMed ID: 32811610
[TBL] [Abstract][Full Text] [Related]
5. Hypercalcemia: A Review.
Walker MD; Shane E
JAMA; 2022 Oct; 328(16):1624-1636. PubMed ID: 36282253
[TBL] [Abstract][Full Text] [Related]
6. Modern management of malignant hypercalcemia.
Legrand SB
Am J Hosp Palliat Care; 2011 Nov; 28(7):515-7. PubMed ID: 21724679
[TBL] [Abstract][Full Text] [Related]
7. [Hypercalcemia].
Dylewska M; Wieliczko M
Wiad Lek; 2013; 66(4):307-10. PubMed ID: 24490483
[TBL] [Abstract][Full Text] [Related]
8. Treatment of Hypercalcemia of Malignancy.
Chakhtoura M; El-Hajj Fuleihan G
Endocrinol Metab Clin North Am; 2021 Dec; 50(4):781-792. PubMed ID: 34774248
[TBL] [Abstract][Full Text] [Related]
9. Elevated levels of circulating fibroblast growth factor 23 with hypercalcemia following discontinuation of denosumab.
Uchida T; Yamaguchi H; Kushima C; Yonekawa T; Nakazato M
Endocr J; 2020 Jan; 67(1):31-35. PubMed ID: 31527321
[TBL] [Abstract][Full Text] [Related]
10. Hypercalcemia: a consultant's approach.
Auron A; Alon US
Pediatr Nephrol; 2018 Sep; 33(9):1475-1488. PubMed ID: 28879535
[TBL] [Abstract][Full Text] [Related]
11. [Treatment of hypercalcaemia].
Andersen TS; Vestergaard P
Ugeskr Laeger; 2014 Apr; 176(9):. PubMed ID: 25096564
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms and treatment of hypercalcemia of malignancy.
Clines GA
Curr Opin Endocrinol Diabetes Obes; 2011 Dec; 18(6):339-46. PubMed ID: 21897221
[TBL] [Abstract][Full Text] [Related]
13. Calcium homeostasis and hyperparathyroidism: Nephrologic and endocrinologic points of view.
Lemoine S; Figueres L; Bacchetta J; Frey S; Dubourg L
Ann Endocrinol (Paris); 2022 Aug; 83(4):237-243. PubMed ID: 35598638
[TBL] [Abstract][Full Text] [Related]
14. Denosumab is Effective for Controlling Serum Calcium Levels in Patients with Humoral Hypercalcemia of Malignancy Syndrome: A Case Report on Parathyroid Hormone-related Protein-producing Cholangiocarcinoma.
Ashihara N; Nakajima K; Nakamura Y; Kobayashi M; Shirahata K; Maeda C; Uehara T; Gomi D; Ito N
Intern Med; 2016; 55(23):3453-3457. PubMed ID: 27904108
[TBL] [Abstract][Full Text] [Related]
15. Denosumab: a new agent in the management of hypercalcemia of malignancy.
Thosani S; Hu MI
Future Oncol; 2015; 11(21):2865-71. PubMed ID: 26403973
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Intravenous Pamidronate for Parathyroid Hormone-dependent Hypercalcemia in Hospitalized Patients.
Rosenblum RC; Twito O; Barzilay-Yoseph L; Ramaty E; Klein N; Rotman-Pikielny P
J Clin Endocrinol Metab; 2021 Oct; 106(11):e4593-e4602. PubMed ID: 34157125
[TBL] [Abstract][Full Text] [Related]
17. Rebound hypercalcemia post-denosumab cessation in metastatic breast cancer.
Wang R; Renouf DA
Osteoporos Int; 2022 Jul; 33(7):1625-1629. PubMed ID: 35286436
[TBL] [Abstract][Full Text] [Related]
18. Ectopic parathyroid hormone as a rare aetiology of hypercalcemia with rhabdomyosarcoma: a new treatment strategy with zoledronic acid and Denosumab.
Kilci F; Demirsoy U; Jones JH; Çakır Ö; Çizmecioğlu-Jones FM
J Pediatr Endocrinol Metab; 2022 Aug; 35(8):1107-1112. PubMed ID: 35534911
[TBL] [Abstract][Full Text] [Related]
19. Use of denosumab to treat refractory hypercalcemia in a peritoneal dialysis patient with immobilization and tertiary hyperparathyroidism.
Pratt RM; West ML; Tennankore KK
Perit Dial Int; 2020 Jan; 40(1):103-106. PubMed ID: 32063140
[TBL] [Abstract][Full Text] [Related]
20. [Therapy of hypercalcemia with ibandronate in case of acute renal failure].
Bergner R; Henrich DM; Hoffmann M; Bruckner D; Uppenkamp M
Internist (Berl); 2006 Mar; 47(3):293-6. PubMed ID: 16470360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]